Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.

Biotechnology

Health Care

Therapeutics

Verismo Therapeutics

Bryan Kim

Andrea Campanile

Raymond Luke

Pavel Aprelev

Jacqueline Stief

Laura A Johnson

The Research and Development team at Verismo Therapeutics is dedicated to innovating and optimizing chimeric antigen receptor (CAR) therapies to improve T-cell-based immunotherapy for cancer. This team collaborates on translational science and strategic guidance, focusing on the discovery and validation of novel CAR designs and their application in the treatment of non-hematologic malignancies with limited therapeutic options.

Research and Development

Leadership Team

Quality and Compliance Team

Research and Development

About

Team members

Other teams at Verismo Therapeutics

Leadership Team

Quality and Compliance Team